Conjugation of a Podoplanin-specific Single-chain Fragment Variable (scFv) to Granzyme B for Designing a Potential Therapeutic Against Malignant Tumors: An In-silico Experiment
Archives of Advances in Biosciences,
Vol. 15 No. 1 (2024),
24 January 2024
,
Page 1-9
https://doi.org/10.22037/aab.v15i1.44359
Abstract
Introduction: Monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs) have changed the face of cancer treatment methods drastically. Herein, I attempted to conjugate a podoplanin (PDPN)-single-chain fragment variable (scFv) to granzyme B (GrB) to design an antibody conjugate (named LpMab-2-(G4S)3-GrB) using in-silico techniques.
Materials and Methods: The 3D models of the PDPN-specific scFv (LpMab-2), LpMab-2-(G4S)3-GrB, and PDPN were predicted by GalaxyWEB, assessed through Ramachandran plot analysis, and refined by 3Drefine. The physicochemical properties, solubility value, and Tm of LpMab-2-(G4S)3-GrB were estimated/predicted and compared with LpMab-2 and GrB. Finally, the binding capacity of LpMab-2-(G4S)3-GrB to PDPN was compared with that of LpMab-2 through docking and affinity prediction alongside identifying the residues that participate in the binding through 2D interaction plots using the LigPlot+ software.
Results: The 3D models were predicted to be of high quality and refined successfully. The solubility and Tm of LpMab-2 were predicted to decrease and increase following its conjugation with GrB, respectively, whereas its estimated half-life was not affected. The docking results indicated that LpMab-2-(G4S)3-GrB targets PDPN in the same orientation as that of LpMab-2 and with the exact same residues as indicated by their 2D plots. Moreover, the affinity of LpMab-2-(G4S)3-GrB to PDPN was predicted to be similar to that of the single scFv.
Conclusion: The conjugation of LpMab-2 to GrB does not affect its binding capacity or characteristics in a major negative fashion. In-silico techniques could be utilized for antibody engineering, and future studies could focus on the assessment of LpMab-2-(G4S)3-GrB in vitro and in vivo.
- Antibody drug conjugate
- Cancer immunotherapy
- Granzyme B
- Podoplanin
- Single chain fragment variable
How to Cite
References
Sehn LH, Herrera AF, Flowers CR, Kamdar MK, McMillan A, Hertzberg M, et al. Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. J Clin Oncol.2020;38(2):155-165. [DOI: 10.1200/JCO.19.00172] [PMID] [PMCID]
Cortés J, Kim SB, Chung WP, Im SA, Park YH, Hegg R, et al. Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer. N Engl J Med. 2022;386(12):1143-1154. [DOI: 10.1056/NEJMoa2115022] [PMID]
Safarzadeh Kozani P, Safarzadeh Kozani P, Rahbarizadeh F. CAR T cells redirected against tumor-specific antigen glycoforms: can low-sugar antigens guarantee a sweet success? Front Med. 2022;16(3):322-338. [DOI: 10.1007/s11684-021-0901-2] [PMID]
He Y, Schreiber K, Wolf SP, Wen F, Steentoft C, Zerweck J, Steiner M, Sharma P, Shepard HM, Posey A, June CH, Mandel U, Clausen H, Leisegang M, Meredith SC, Kranz DM, Schreiber H. Multiple cancer-specific antigens are targeted by a chimeric antigen receptor on a single cancer cell. JCI Insight. 2019;4(21):e130416. [DOI: 10.1172/jci.insight.130416] [PMID] [PMCID]
Kato Y, Kaneko MK. A cancer-specific monoclonal antibody recognizes the aberrantly glycosylated podoplanin. Sci Rep. 2014;4:5924. [DOI: 10.1038/srep05924] [PMID] [PMCID]
Rousalova I, Krepela E. Granzyme B-induced apoptosis in cancer cells and its regulation (review). Int J Oncol. 2010;37(6):1361-78. [DOI: 10.3892/ijo_00000788] [PMID]
Ko J, Park H, Heo L, Seok C. GalaxyWEB server for protein structure prediction and refinement. Nucleic Acids Res. 2012 Jul;40(Web Server issue):W294-7. [DOI: 10.1093/nar/gks493] [PMID] [PMCID]
Studer G, Rempfer C, Waterhouse AM, Gumienny R, Haas J, Schwede T. QMEANDisCo-distance constraints applied on model quality estimation. Bioinformatics. 2020;36(6):1765-1771. [DOI: 10.1093/bioinformatics/btz828] [PMID] [PMCID]
Williams CJ, Headd JJ, Moriarty NW, Prisant MG, Videau LL, Deis LN, et al. MolProbity: More and better reference data for improved all-atom structure validation. Protein Sci. 2018;27(1):293-315. [DOI: 10.1002/pro.3330] [PMID] [PMCID]
Bhattacharya D, Nowotny J, Cao R, Cheng J. 3Drefine: an interactive web server for efficient protein structure refinement. Nucleic Acids Res. 2016;44(W1):W406-9. [DOI: 10.1093/nar/gkw336] [PMID] [PMCID]
Hebditch M, Carballo-Amador MA, Charonis S, Curtis R, Warwicker J. Protein-Sol: a web tool for predicting protein solubility from sequence. Bioinformatics. 2017;33(19):3098-3100. [DOI: 10.1093/bioinformatics/btx345] [PMID] [PMCID]
Brenke R, Hall DR, Chuang GY, Comeau SR, Bohnuud T, Beglov D, Schueler-Furman O, Vajda S, Kozakov D. Application of asymmetric statistical potentials to antibody-protein docking. Bioinformatics. 2012;28(20):2608-14. [DOI: 10.1093/bioinformatics/bts493] [PMID] [PMCID]
Kozakov D, Hall DR, Xia B, Porter KA, Padhorny D, Yueh C, Beglov D, Vajda S. The ClusPro web server for protein-protein docking. Nat Protoc. 2017;12(2):255-278. [DOI: 10.1038/nprot.2016.169] [PMID] [PMCID]
Xue LC, Rodrigues JP, Kastritis PL, Bonvin AM, Vangone A. PRODIGY: a web server for predicting the binding affinity of protein-protein complexes. Bioinformatics. 2016;32(23):3676-3678. [DOI: 10.1093/bioinformatics/btw514] [PMID]
Quintanilla M, Montero-Montero L, Renart J, Martín-Villar E. Podoplanin in Inflammation and Cancer. Int J Mol Sci. 2019;20(3):707. [DOI: 10.3390/ijms20030707] [PMID] [PMCID]
Suzuki H, Kaneko MK, Kato Y. Roles of Podoplanin in Malignant Progression of Tumor. Cells. 2022;11(3):575. [DOI: 10.3390/cells11030575] [PMID] [PMCID]
Shiina S, Ohno M, Ohka F, Kuramitsu S, Yamamichi A, Kato A, Motomura K, et al. CAR T Cells Targeting Podoplanin Reduce Orthotopic Glioblastomas in Mouse Brains. Cancer Immunol Res. 2016;4(3):259-68. [DOI: 10.1158/2326-6066.CIR-15-0060] [PMID]
Abe S, Kaneko MK, Tsuchihashi Y, Izumi T, Ogasawara S, Okada N, et al. Antitumor effect of novel anti-podoplanin antibody NZ-12 against malignant pleural mesothelioma in an orthotopic xenograft model. Cancer Sci. 2016;107(9):1198-205. [DOI: 10.1111/cas.12985] [PMID] [PMCID]
- Abstract Viewed: 262 times
- pdf Downloaded: 103 times